Morningstar

Tema Oncology ETF CANC

Morningstar Medalist Rating
Medalist Rating as of | See Tema Global Investment Hub

Morningstar’s Analysis CANC

Will CANC outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable CANC’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the CANC management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of CANC’s parent organization’s priorities and whether they’re in line with investors’ interests.

The combination of a middling Process Pillar rating and a Below Average People Pillar rating limit Tema Oncology ETF to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CANC

More CANC Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 40.7
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Regeneron Pharmaceuticals Inc

5.85 2.9 Mil
Healthcare

AstraZeneca PLC

5.51 2.7 Mil
Healthcare

Amgen Inc

4.50 2.2 Mil
Healthcare

argenx SE ADR

3.95 1.9 Mil
Healthcare

Merck & Co Inc

3.91 1.9 Mil
Healthcare

Chugai Pharmaceutical Co Ltd

3.53 1.7 Mil
Healthcare

Illumina Inc

3.39 1.7 Mil
Healthcare

Gilead Sciences Inc

3.36 1.6 Mil
Healthcare

Daiichi Sankyo Co Ltd

3.29 1.6 Mil
Healthcare

Revolution Medicines Inc Ordinary Shares

3.27 1.6 Mil
Healthcare

Sponsor Center